Annotation Detail for LRRC40

Basic Information
Top
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D016572 |
Cyclosporine |
Cyclosporine results in decreased expression of LRRC40 mRNA | decreases expression | 20106945
|
D006830 |
Hydralazine |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC40 mRNA | affects cotreatment|increases expression | 17183730
|
D014635 |
Valproic Acid |
[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC40 mRNA | affects cotreatment|increases expression | 17183730
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000014 |
Abnormalities, Drug-Induced |
|
Valproic Acid |
4.23 | 8875741 |
MESH:D000015 |
Abnormalities, Multiple |
|
Valproic Acid |
4.41 | 19490988 |
MESH:D000550 |
Amblyopia |
|
Valproic Acid |
6.10 | 17688650 |
MESH:D001008 |
Anxiety Disorders |
|
Valproic Acid |
3.94 | 17497229 |
MESH:D001321 |
Autistic Disorder |
|
Valproic Acid |
1.98 | 18396377 17157402 16609825 18985861 18940202 18316065 18775368 17507914 19460635 15238991 19232924 20603192 18177632 18558336 17688650 |
MESH:D001714 |
Bipolar Disorder |
|
Valproic Acid |
3.26 | 20046352 17594078 |
MESH:D001848 |
Bone Diseases, Developmental |
|
Valproic Acid |
3.66 | 8888407 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
2.82 | 12371664 |
MESH:D002659 |
Child Development Disorders, Pervasive |
|
Valproic Acid |
2.83 | 20734317 |
MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.24 | 19486331 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Valproic Acid |
1.91 | 17688650 8888407 16575769 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Valproic Acid |
2.26 | 19641884 1733752 |
MESH:D004421 |
Dystonia |
|
Valproic Acid |
4.58 | 1851702 |
MESH:D004831 |
Epilepsies, Myoclonic |
|
Valproic Acid |
4.81 | 17275665 3659116 |
MESH:D004828 |
Epilepsies, Partial |
|
Valproic Acid |
4.78 | 3922381 16628512 |
MESH:D004827 |
Epilepsy |
|
Valproic Acid |
3.12 | 20417680 18234410 |
MESH:D004832 |
Epilepsy, Absence |
|
Valproic Acid |
4.00 | 6426943 7562514 6254150 |
MESH:D017029 |
Epilepsy, Complex Partial |
|
Valproic Acid |
4.95 | 7750514 |
MESH:D004830 |
Epilepsy, Tonic-Clonic |
|
Valproic Acid |
4.81 | 3659116 |
MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
9.41 | 19224547 |
MESH:D005234 |
Fatty Liver |
|
Valproic Acid |
9.41 | 14986274 19224547 |
MESH:D005315 |
Fetal Diseases |
|
Valproic Acid |
5.75 | 16575769 |
MESH:D005317 |
Fetal Growth Retardation |
|
Valproic Acid |
4.71 | 18558336 8888407 |
MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.79 | 12639820 12168785 |
MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.96 | 8708960 |
MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.16 | 15720958 |
MESH:D006849 |
Hydrocephalus |
|
Valproic Acid |
5.61 | 17688650 |
MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.23 | 10903974 |
MESH:D046110 |
Hypertension, Pregnancy-Induced |
|
Hydralazine |
5.28 | 16612254 |
MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.31 | 15604871 |
MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.56 | 18776723 10903974 8314463 |
MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.12 | 12371664 |
MESH:D015470 |
Leukemia, Myeloid, Acute |
|
Valproic Acid |
2.20 | 16294345 17596541 |
MESH:D017563 |
Lung Diseases, Interstitial |
|
Valproic Acid |
5.13 | 17228818 |
MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.65 | 16801185 |
MESH:D008881 |
Migraine Disorders |
|
Valproic Acid |
3.50 | 18765137 18803445 |
MESH:D009139 |
Musculoskeletal Abnormalities |
|
Valproic Acid |
4.51 | 8888407 |
MESH:D009190 |
Myelodysplastic Syndromes |
|
Valproic Acid |
3.37 | 17596541 |
MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.31 | 17954296 |
MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.70 | 19348381 18481113 |
MESH:D009436 |
Neural Tube Defects |
|
Valproic Acid |
3.39 | 16359493 8888407 |
MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.64 | 12371664 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Valproic Acid |
4.57 | 20603192 |
MESH:D019310 |
Pseudolymphoma |
|
Valproic Acid |
5.41 | 11422049 12752131 |
MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.34 | 16882103 |
MESH:D012208 |
Rhabdomyosarcoma |
|
Valproic Acid |
4.70 | 19155313 |
MESH:D012559 |
Schizophrenia |
|
Valproic Acid |
2.11 | 19110320 15737665 |
MESH:D012640 |
Seizures |
|
Valproic Acid |
3.02 | 11044598 16876388 1511512 14763951 3137016 11738929 17978042 15475178 |
MESH:D016135 |
Spinal Dysraphism |
|
Valproic Acid |
4.13 | 19490988 |
MESH:D013226 |
Status Epilepticus |
|
Valproic Acid |
5.41 | 12833885 |
MESH:D014178 |
Translocation, Genetic |
|
Valproic Acid |
6.10 | 17262798 |
MESH:D020194 |
Unverricht-Lundborg Syndrome |
|
Valproic Acid |
5.26 | 3119515 |
MESH:D014564 |
Urogenital Abnormalities |
|
Valproic Acid |
5.30 | 8888407 |
MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.85 | 1336536 |
MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.31 | 17120751 |